Q1 Earnings Estimate for CAPR Issued By HC Wainwright

Capricor Therapeutics Inc (NASDAQ:CAPR) – Research analysts at HC Wainwright issued their Q1 2025 earnings estimates for shares of Capricor Therapeutics in a research note issued to investors on Thursday, March 20th. HC Wainwright analyst J. Pantginis expects that the biotechnology company will post earnings per share of ($0.35) for the quarter. HC Wainwright has a “Buy” rating and a $77.00 price target on the stock. The consensus estimate for Capricor Therapeutics’ current full-year earnings is ($1.21) per share. HC Wainwright also issued estimates for Capricor Therapeutics’ Q3 2025 earnings at $0.94 EPS, Q4 2025 earnings at ($0.39) EPS, FY2025 earnings at $0.15 EPS and FY2026 earnings at ($0.61) EPS.

Capricor Therapeutics (NASDAQ:CAPR) last posted its quarterly earnings results on Wednesday, March 19th. The biotechnology company reported ($0.16) earnings per share for the quarter, beating the consensus estimate of ($0.31) by $0.15. Capricor Therapeutics had a negative net margin of 146.86% and a negative return on equity of 112.95%. The firm had revenue of $11.13 million during the quarter, compared to the consensus estimate of $9.87 million.

Separately, Cantor Fitzgerald restated an “overweight” rating and set a $30.00 price target on shares of Capricor Therapeutics in a research note on Thursday, March 20th. One analyst has rated the stock with a sell rating and six have issued a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $34.50.

Capricor Therapeutics Stock Up 3.3 %

Shares of NASDAQ CAPR opened at $13.28 on Monday. Capricor Therapeutics has a twelve month low of $3.52 and a twelve month high of $23.40. The firm has a market cap of $603.84 million, a PE ratio of -12.53 and a beta of 4.10. The business has a fifty day simple moving average of $14.07 and a two-hundred day simple moving average of $14.76.

Institutional Investors Weigh In On Capricor Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the stock. Wellington Management Group LLP bought a new position in Capricor Therapeutics in the fourth quarter worth about $565,000. California State Teachers Retirement System boosted its stake in Capricor Therapeutics by 1,653.0% in the fourth quarter. California State Teachers Retirement System now owns 32,237 shares of the biotechnology company’s stock valued at $445,000 after acquiring an additional 30,398 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC purchased a new position in Capricor Therapeutics in the fourth quarter worth $462,000. Voloridge Investment Management LLC acquired a new position in shares of Capricor Therapeutics during the fourth quarter worth $1,678,000. Finally, Woodline Partners LP purchased a new stake in shares of Capricor Therapeutics during the 4th quarter valued at $8,693,000. Institutional investors own 21.68% of the company’s stock.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.